November 28, 2016 - By Linda Rogers · 0 Comments
The stock of Catabasis Pharmaceuticals Incorporated (NASDAQ:CATB) registered an increase of 67.28% in short interest. CATB’s total short interest was 379,400 shares in November as published by FINRA. Its up 67.28% from 226,800 shares, reported previously. With 79,500 shares average volume, it will take short sellers 5 days to cover their CATB’s short positions. The short interest to Catabasis Pharmaceuticals Incorporated’s float is 5.65%. About 28,668 shares traded hands. Catabasis Pharmaceuticals Inc (NASDAQ:CATB) has declined 22.38% since April 25, 2016 and is downtrending. It has underperformed by 28.39% the S&P500.
Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $71.72 million. The Firm is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted , a linker drug discovery platform. It currently has negative earnings. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
Out of 2 analysts covering Catabasis Pharmaceuticals (NASDAQ:CATB), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Catabasis Pharmaceuticals has been the topic of 4 analyst reports since August 17, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by Wedbush given on Monday, August 17. Wedbush maintained Catabasis Pharmaceuticals Inc (NASDAQ:CATB) rating on Wednesday, June 8. Wedbush has “Outperform” rating and $17 price target. The stock of Catabasis Pharmaceuticals Inc (NASDAQ:CATB) has “Buy” rating given on Thursday, June 9 by Citigroup. Citigroup maintained the stock with “Buy” rating in Tuesday, March 22 report.
Catabasis Pharmaceuticals, Inc., incorporated on June 26, 2008, is a clinical-stage biopharmaceutical company. The Firm is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease. The Company’s primary focus is on treatments for rare diseases. The Firm is also developing other product candidates for the treatment of lipid disorders. The Company’s CAT-1004 is a SMART linker conjugate of salicylate, a non-steroidal anti-inflammatory drug, and the omega-3 fatty acid docosahexaenoic acid (DHA), a naturally occurring unsaturated fatty acid with anti-inflammatory properties. The Company’s CAT-2000 series product candidates inhibit the Sterol Regulatory Element Binding Protein (SREBP) pathway. The Company’s CAT-4001 is a SMART linker conjugate of monomethyl fumarate and DHA.
More notable recent Catabasis Pharmaceuticals Inc (NASDAQ:CATB) news were published by: Marketwatch.com which released: “Catabasis shares plummet 51% after drug trial misses goal” on April 24, 2015, also Quotes.Wsj.com with their article: “News Catabasis Pharmaceuticals Inc.CATB” published on February 02, 2015, Globenewswire.com published: “Catabasis Pharmaceuticals, Inc. (Nasdaq: CATB) to Ring The Nasdaq Stock Market …” on November 16, 2016. More interesting news about Catabasis Pharmaceuticals Inc (NASDAQ:CATB) were released by: Businesswire.com and their article: “Catabasis Pharmaceuticals Initiates MoveDMD, a Phase 1/2 Trial of CAT-1004 for …” published on June 17, 2015 as well as Barrons.com‘s news article titled: “Catabasis Pharmaceuticals Shares Could Double” with publication date: July 20, 2015.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Linda Rogers